Abstract:Protein-tyrosine phosphatase nonreceptor type 22 (PTPN22) is a lymphoid-specific tyrosine phosphatase (LYP), and mutations in the PTPN22 gene are highly correlated with a spectrum of autoimmune diseases. However, compounds and mechanisms that specifically inhibit LYP enzymes to address therapeutic needs to manage these diseases remain to be discovered. Here, we conducted a similarity search of a commercial database for PTPN22 inhibitors and identified several LYP inhibitor scaffolds, which helped identify one highly active inhibitor, NC1. Using noncompetitive inhibition curve and phosphatase assays, we determined NC1's inhibition mode toward PTPN22 and its selectivity toward a panel of phosphatases. We found that NC1 is a noncompetitive LYP inhibitor and observed that it exhibits selectivity against other protein phosphatases and effectively inhibits LYP activity in lymphoid T cells and modulates T-cell receptor signaling. Results from site-directed mutagenesis, fragment-centric topographic mapping, and molecular dynamics simulation experiments suggested that NC1, unlike other known LYP inhibitors, concurrently binds to a "WPD" pocket and a second pocket surrounded by an LYP-specific insert, which contributes to its selectivity against other phosphatases. Moreover, using a newly developed method to incorporate the unnatural amino acid 2-fluorine-tyrosine and 19F NMR spectroscopy, we provide direct evidence that NC1 allosterically regulates LYP activity by restricting WPD-loop movement. In conclusion, our approach has identified a new allosteric binding site in LYP useful for selective LYP inhibitor development; we propose that the 19F NMR probe developed here may also be useful for characterizing allosteric inhibitors of other tyrosine phosphatases.

Development of Novel Phosphonodifluoromethyl-Containing Phosphotyrosine Mimetics and a First-In-Class, Potent, Selective, and Bioavailable Inhibitor of Human CDC14 Phosphatases

Identification and Structure-Function Analyses of an Allosteric Inhibitor of the Tyrosine Phosphatase PTPN22.

Structural Basis for Inhibition of the Protein Tyrosine Phosphatase 1B by Phosphotyrosine Peptide Mimetics.

Structure-Based Discovery of Small Molecule Inhibitors Targeted to Protein Tyrosine Phosphatase 1B

Proteomic Identification of Protein Tyrosine Phosphatase and Substrate Interactions in Living Mammalian Cells by Genetic Encoding of Irreversible Enzyme Inhibitors

Discovery and Sar of A Novel Selective and Orally Bioavailable Nonpeptide Classical Competitive Inhibitor Class of Protein-Tyrosine Phosphatase 1B

Exploring the Existing Drug Space for Novel Ptyr Mimetic and SHP2 Inhibitors.

Identification of a Benzo Imidazole Thiazole Derivative As the Specific Irreversible Inhibitor of Protein Tyrosine Phosphatase.

Synthesis and cell-based activity of a potent and selective protein tyrosine phosphatase 1B inhibitor prodrug.

1H-2,3-dihydroperimidine Derivatives: A New Class of Potent Protein Tyrosine Phosphatase 1B Inhibitors

Design and Biological Evaluation of Novel Imidazolyl Flavonoids As Potent and Selective Protein Tyrosine Phosphatase Inhibitors.

Discovery of Core-Structurally Novel PTP1B Inhibitors with Specific Selectivity Containing Oxindole-Fused Spirotetrahydrofurochroman by One-Pot Reaction.

Structure-Based Design of Active-Site-Directed, Highly Potent, Selective, and Orally Bioavailable Low-Molecular-Weight Protein Tyrosine Phosphatase Inhibitors.

Recent Advances in the Development of Allosteric Protein Tyrosine Phosphatase Inhibitors for Drug Discovery.

An Affinity-Based Fluorescence Polarization Assay for Protein Tyrosine Phosphatases.

Synthesis and Biological Evaluation of (±)-3-(2-(2-fluorobenzyloxy) Naphthalen-6-yl)-2-aminopropanoic Acid Derivatives As Novel PTP1B Inhibitors.

Structure-Based Design and Synthesis of Small Molecule Protein-Tyrosine Phosphatase 1b Inhibitors

Discovering the Distinct Inhibitory Effects Between C4-epimeric Glycosyl Amino Acids: New Insight into the Development of Protein Tyrosine Phosphatase Inhibitors

Drugging Protein Tyrosine Phosphatases through Targeted Protein Degradation

Targeting PTPs with small molecule inhibitors in cancer treatment

Potent and highly selective inhibitors of the protein tyrosine phosphatase 1B.